Heinzel, Frank R.
Shah, Sanjiv J.
Article History
Accepted: 19 May 2022
First Online: 29 June 2022
Declarations
:
: F. R. Heinzel has received consulting fees from Abbott, Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Menarini and Novartis, sponsoring from Bristol-Myers Squibb and Servier, and has been involved in research co-operations with Sanofi, Lexicon and Orion Pharma. S. J. Shah has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Aria CV, Axon Therapies, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, Coridea, CVRx, Cyclerion, Cytokinetics, Edwards Lifesciences, Eidos, Eisai, Imara, Impulse Dynamics, Intellia, Ionis, Ironwood, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Prothena, Regeneron, Rivus, Sanofi, Shifamed, Tenax, Tenaya, and United Therapeutics.
: For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.